Gilead Sciences, Inc.
GILD · US
GILD Research Preview
| Metric | Reading |
|---|---|
| Price | $123.76 |
| Daily move | -1.35% |
| Strategy score | 59/100 (Hold) |
| Trend | Consolidation |
| RSI14 / RSI6 | 51.02 / 60.78 (neutral) |
| MACD (line / signal / hist) | -0.79 / -1.29 / +0.50 |
| Estimated support | $128.36 |
| Estimated resistance | $136.19 |
| 30-session range position | -29.13% (below range low 127.64) |
| Data confidence | Moderate (fundamentals High; EV/EBITDA Low; no social sentiment) |
| Indicator | Reading | Read |
|---|---|---|
| MA (5/10/20/60) | 132.59 / 131.78 / 132.27 / 137.20 | Mixed alignment (MA5 > MA10 > MA20 > MA60); price -6.44% below MA20 |
| RSI (14 / 6) | 51.02 / 60.78 | Neutral momentum; faster RSI6 firmer |
| MACD (line/signal/hist) | -0.79 / -1.29 / +0.50 | Bullish configuration; crossover below zero line, momentum building |
| KDJ (K/D/J) | 54.51 / 43.63 / 76.27 | Constructive crossover (K above D) |
| Bollinger (U/M/L) | 136.19 / 132.27 / 128.36 | Price near/under lower band (-59% of band) |
| ATR14 / ATR14% | 3.33 / +2.49% | Moderate volatility relative to price |
| OBV / slope | 19,162,122.70 / +38.38% | Accumulation improving |
| CCI20 | 73.87 | Inside neutral band |
What is confirmed: Momentum oscillators (MACD histogram, KDJ crossover) and the OBV slope agree on improving short-term momentum and accumulation. RSI sits squarely neutral, corroborating the consolidation label.
What is conflicted: Trend versus location. Crossover-based scores read constructively, but price is below every moving average and beneath the lower Bollinger band, which is not typical of a healthy uptrend. The OBV improvement also coincides with current volume running -17.58% under the 20-session average (12.46M vs 6.11M average - note the latest session volume is above average even though the smoothed comparison reads soft), so the accumulation signal is worth tracking but not yet decisive.
What is missing: No volume-by-price or longer-horizon trend confirmation was supplied, and no custom indicators were provided, so this section relies on the standard panel above.
| Axis | Reading | Source | Confidence |
|---|---|---|---|
| PE | 18.25 | SEC EDGAR companyfacts | Medium |
| PB | 6.61 | SEC EDGAR companyfacts | Medium |
| Price / sales | 5.28 | SEC EDGAR companyfacts | Medium |
| EV/EBITDA | 17.17 | SEC EDGAR companyfacts | Low |
| PEG proxy | 1.01 | StockKit scenario model | Medium |
| StockKit fair value range | Bear $135.95 / Base $186.96 / Bull $234.91 | StockKit DCF scenario model | Medium |
| Base fair-value gap | +51.1% | StockKit DCF scenario model | Medium |
| 5Y growth forecast | Bear +10.00% / Base +18.00% / Bull +24.00% | StockKit scenario model | Medium |
| Revenue | $29.44B | SEC EDGAR companyfacts | High |
| Net income | $8.51B | SEC EDGAR companyfacts | High |
| Market cap | $155.32B | SEC shares outstanding + live quote | Medium |
| Balance sheet context | Assets $56.28B / Equity $23.52B | SEC EDGAR companyfacts | High |
The fair-value range and the +51.1% base gap are StockKit DCF scenario outputs computed from reported fundamentals - they are internally modeled forecasts, not analyst consensus targets, and should be weighed accordingly. A PEG proxy of 1.01 against a base 5Y growth assumption of +18.00% frames the multiple as roughly in line with modeled growth. EV/EBITDA carries Low confidence and should be treated as indicative only.
Confirmed headlines (supplied):
| Date | Headline | Source | Why it matters |
|---|---|---|---|
| 2026-06-17 | Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years | Biztoc.com | Retrospective performance piece; sentiment/attention signal, no new operating fact |
| 2026-06-17 | Gilead Sciences (GILD) Donates Remdesivir to Uganda | Yahoo Entertainment | Company-specific action touching reputation and access programs; not a disclosed financial event |
| 2026-06-16 | Dorio channels pure momentum on "New Energy" | Earmilk.com | Music/entertainment item, not GILD-relevant; noise |
| 2026-06-13 | Wells Fargo Calls MannKind (MNKD)'s Commercial Potential a "Show-Me Story" | Yahoo Entertainment | Sector-adjacent commentary on a different company; no direct GILD read-through |
| 2026-06-11 | Is COMPASS Pathways (CMPS) A Good Stock To Buy Now? | Yahoo Entertainment | Peer/biotech coverage on a different name; context only |
Missing data: No earnings date, regulatory decision, guidance update, or analyst-rating action was supplied. Of the five headlines, only two are GILD-specific and neither is a disclosed financial catalyst, so the near-term catalyst calendar is effectively empty in this dataset. Catalyst confidence is low.
| Source | Status | Reading | Confidence |
|---|---|---|---|
| NewsAPI headline coverage | 5 headlines | Yahoo Entertainment x3, Biztoc.com x1, Earmilk.com x1 | Medium |
| Social sentiment | Not connected | No social sentiment conclusion is drawn | Low |
No provider-level sentiment score was returned for this symbol. Headline coverage is sparse and skewed toward retrospective and peer items rather than fresh GILD operating news. Because social sentiment is not connected, no Reddit, X, StockTwits, or forum reading is available or inferred. Overall sentiment confidence is low.
| Scenario | Trigger condition | What would confirm it | What would invalidate it |
|---|---|---|---|
| Base (consolidation) | Price holds the 123-128 zone with neutral RSI14 (51.02) and positive MACD histogram (0.50) | Sustained close back above support $128.36 and the MA20 at 132.27; OBV slope stays positive | Decisive close below the 30-session low (127.64) extending the -29.13% range position |
| Upside | Reclaim of $128.36 followed by momentum continuation toward resistance $136.19 | KDJ crossover (54.51/43.63) and MACD strengthen while price clears MA60 (137.20) and tests upper band (136.19); volume expands above the 20-session average (6.11M) | Failure at MA20 (132.27) with MACD histogram rolling back negative |
| Downside | Continued trade below the lower Bollinger band (128.36) with volume confirmation | Price loses the 30-session low (127.64) and OBV slope flattens or turns down from +38.38% | Quick recovery above $128.36 and RSI14 holding above 50 |
| Risk | Evidence | Trigger | Monitoring action |
|---|---|---|---|
| Trend breakdown | Price -6.44% below MA20 and below all MAs; -29.13% within 30-session range | Daily close below 127.64 | Track support 128.36 and range low daily |
| False momentum signal | MACD/KDJ flag bullish while price sits under lower band | MACD histogram (0.50) reverts negative | Watch histogram and KDJ K/D for a re-cross |
| Thin catalyst/sentiment coverage | Only 2 of 5 headlines GILD-specific; social sentiment not connected | New disclosed event lands outside this dataset | Monitor for earnings/regulatory updates not yet supplied |
| Valuation-model reliance | Base fair-value gap +51.1% is StockKit DCF output, not consensus; EV/EBITDA Low confidence | Reported fundamentals diverge from model inputs | Treat fair-value range as modeled, recheck against fresh filings |
| Volatility | ATR14 = 3.33 (+2.49% of price) | ATR% expands materially | Size watch levels against ATR, not fixed ticks |
MA5>MA20金叉
MACD金叉，MACD在零轴下方，动能增强
RSI14=51中性
在通道中部
缩量回调，可能企稳
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
Biztoc.com · 2026-06-17
Gilead Sciences (GILD) Donates Remdesivir to Uganda
Yahoo Entertainment · 2026-06-17
Dorio channels pure momentum on “New Energy” [Interview]
Earmilk.com · 2026-06-16
Wells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story”
Yahoo Entertainment · 2026-06-13
Is COMPASS Pathways plc (CMPS) A Good Stock To Buy Now?
Yahoo Entertainment · 2026-06-11
Research boundary
StockKit organizes market data and model output for research workflows. It does not provide personalized advice or trade instructions. Verify important information with primary sources before any investment decision.